Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
Abstract: The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/ref...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924005585 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595753834381312 |
|---|---|
| author | Julia M. Unglaub Richard F. Schlenk Jan Moritz Middeke Stefan W. Krause Sabrina Kraus Hermann Einsele Michael Kramer Sven Zukunft Joseph Kauer Simon Renders Elena Katelari Christoph Schliemann Caroline Pabst Thomas Luft Peter Dreger Christoph Röllig Martin Bornhäuser Carsten Müller-Tidow Tim Sauer |
| author_facet | Julia M. Unglaub Richard F. Schlenk Jan Moritz Middeke Stefan W. Krause Sabrina Kraus Hermann Einsele Michael Kramer Sven Zukunft Joseph Kauer Simon Renders Elena Katelari Christoph Schliemann Caroline Pabst Thomas Luft Peter Dreger Christoph Röllig Martin Bornhäuser Carsten Müller-Tidow Tim Sauer |
| author_sort | Julia M. Unglaub |
| collection | DOAJ |
| description | Abstract: The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/refractory (R/R) AML; however, comparative studies with conventional therapies for fit patients as a bridge-to-transplant strategy are limited. Using propensity score matching (PSM), we compared 37 patients with R/R AML, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT), with 90 patients from the German Study Alliance Leukemia AML registry, who were treated with non–VEN-containing salvage therapy according to their treating physician’s choice (TPC). The overall response rate among VEN patients was higher than the TPC control cohort (62% vs 42%; P = .049). Overall, 73% of VEN-treated patients vs 63% of TPC patients were bridged to allo-HCT (P = .41). After a median follow-up of 34.3 months for the VEN and 21.0 months for the TPC cohort, the median overall survival (OS) were 15.8 months (95% confidence interval [CI], 10.6 to not evaluable) and 10.5 months (95% CI, 6.8-19.6; P = .15), respectively. PSM revealed a trend toward improved OS for VEN patients (hazard ratio, 0.70; 95% CI, 0.41-1.22; P = .20). Median event-free survival was significantly longer in the VEN cohort (8.0 months) than the TPC cohort (3.7 months; P = .006). Our data suggest that VEN-based salvage therapy is a safe and effective bridge to allo-HCT for this difficult-to-treat AML patient population. |
| format | Article |
| id | doaj-art-585e9ee4ea354e2d8b3c19eaa34854ed |
| institution | Kabale University |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-585e9ee4ea354e2d8b3c19eaa34854ed2025-01-18T05:04:58ZengElsevierBlood Advances2473-95292025-01-0192375385Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AMLJulia M. Unglaub0Richard F. Schlenk1Jan Moritz Middeke2Stefan W. Krause3Sabrina Kraus4Hermann Einsele5Michael Kramer6Sven Zukunft7Joseph Kauer8Simon Renders9Elena Katelari10Christoph Schliemann11Caroline Pabst12Thomas Luft13Peter Dreger14Christoph Röllig15Martin Bornhäuser16Carsten Müller-Tidow17Tim Sauer18Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, GermanyDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany; National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, GermanyDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, GermanyDepartment of Hematology and Medical Oncology, University Hospital Erlangen, Erlangen, GermanyDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, GermanyDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, GermanyDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, GermanyDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, GermanyDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, GermanyDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, GermanyDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, GermanyDepartment of Medicine A, University Hospital Münster, Münster, GermanyDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, GermanyDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, GermanyDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, GermanyDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, GermanyDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany; National Center for Tumor Diseases Dresden, Dresden, GermanyDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, GermanyDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany; Correspondence: Tim Sauer, Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany;Abstract: The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/refractory (R/R) AML; however, comparative studies with conventional therapies for fit patients as a bridge-to-transplant strategy are limited. Using propensity score matching (PSM), we compared 37 patients with R/R AML, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT), with 90 patients from the German Study Alliance Leukemia AML registry, who were treated with non–VEN-containing salvage therapy according to their treating physician’s choice (TPC). The overall response rate among VEN patients was higher than the TPC control cohort (62% vs 42%; P = .049). Overall, 73% of VEN-treated patients vs 63% of TPC patients were bridged to allo-HCT (P = .41). After a median follow-up of 34.3 months for the VEN and 21.0 months for the TPC cohort, the median overall survival (OS) were 15.8 months (95% confidence interval [CI], 10.6 to not evaluable) and 10.5 months (95% CI, 6.8-19.6; P = .15), respectively. PSM revealed a trend toward improved OS for VEN patients (hazard ratio, 0.70; 95% CI, 0.41-1.22; P = .20). Median event-free survival was significantly longer in the VEN cohort (8.0 months) than the TPC cohort (3.7 months; P = .006). Our data suggest that VEN-based salvage therapy is a safe and effective bridge to allo-HCT for this difficult-to-treat AML patient population.http://www.sciencedirect.com/science/article/pii/S2473952924005585 |
| spellingShingle | Julia M. Unglaub Richard F. Schlenk Jan Moritz Middeke Stefan W. Krause Sabrina Kraus Hermann Einsele Michael Kramer Sven Zukunft Joseph Kauer Simon Renders Elena Katelari Christoph Schliemann Caroline Pabst Thomas Luft Peter Dreger Christoph Röllig Martin Bornhäuser Carsten Müller-Tidow Tim Sauer Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML Blood Advances |
| title | Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML |
| title_full | Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML |
| title_fullStr | Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML |
| title_full_unstemmed | Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML |
| title_short | Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML |
| title_sort | venetoclax based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed refractory aml |
| url | http://www.sciencedirect.com/science/article/pii/S2473952924005585 |
| work_keys_str_mv | AT juliamunglaub venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT richardfschlenk venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT janmoritzmiddeke venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT stefanwkrause venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT sabrinakraus venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT hermanneinsele venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT michaelkramer venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT svenzukunft venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT josephkauer venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT simonrenders venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT elenakatelari venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT christophschliemann venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT carolinepabst venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT thomasluft venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT peterdreger venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT christophrollig venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT martinbornhauser venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT carstenmullertidow venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml AT timsauer venetoclaxbasedsalvagetherapyasabridgetotransplantisfeasibleandeffectiveinpatientswithrelapsedrefractoryaml |